Workflow
山东药玻(600529):模制瓶增速趋缓,龙头优势仍稳固
600529SPG(600529) 天风证券·2025-04-26 09:15

Investment Rating - The report maintains a "Buy" rating for the company [4][7][22] Core Views - The company achieved a revenue of 5.125 billion yuan and a net profit attributable to shareholders of 942.99 million yuan in 2024, representing a year-on-year growth of 2.87% and 21.55% respectively [1] - The company’s core profit, excluding non-recurring items, reached 904 million yuan, with a year-on-year increase of 21.86% [1] - The company is expected to benefit from the continuous increase in the penetration rate of borosilicate glass, which is anticipated to sustain high demand in downstream markets [4] Financial Performance Summary - In 2024, the company’s revenue from various products was as follows: molded bottles 2.35 billion yuan (+3.9%), brown bottles 1.16 billion yuan (+3.5%), ampoules 70 million yuan (-6.0%), controlled bottles 210 million yuan (+5.0%), butyl rubber stoppers 290 million yuan (+11.9%), and aluminum-plastic cover plastic bottles 60 million yuan (-0.6%) [2] - The overall gross margin for 2024 was 31.72%, an increase of 3.69 percentage points year-on-year [3] - The company’s operating cash flow net amount was 1.165 billion yuan, an increase of 117 million yuan year-on-year, with a cash collection ratio of 99.09% [3] Future Earnings Forecast - The company’s projected net profit attributable to shareholders for 2025-2027 is revised to 1.145 billion yuan, 1.348 billion yuan, and 1.566 billion yuan respectively [4] - The expected earnings per share (EPS) for 2025-2027 are 1.73 yuan, 2.03 yuan, and 2.36 yuan respectively [6][17]